Successful Phase 2 clinical trial of ISLA-101 achieves anti-dengue activity in humans
• Highly encouraging phase 2a/b top-line results advocate for the continued clinical development of ISLA-101 in dengue virus
• ISLA-101 associated with meaningful reduction in both viremia (viral load) and symptoms in preventative cohort
• Treatment cohort demonstrated signals of drug effect
• Investor webinar scheduled for Tuesday, 17 June at 11:00am AEST
Ann: Successful Phase 2 clinical trial of ISLA-101, page-2
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
-0.010(6.25%) |
Mkt cap ! $37.08M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 14.5¢ | $99.96K | 664.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 206896 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 18900 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| ILA (ASX) Chart |